Page 2 - பெண்கள் மருத்துவமனை இதயம் வாஸ்குலர் மையம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Sotagliflozin reduces adverse cardiovascular events across patients with diabetes, heart failure Patients with both diabetes and heart failure who were treated with sotagliflozin, a novel investigational drug for diabetes, for a median of nine to 16 months experienced reductions of 22% to 43% in the risk of death or worsening heart failure compared with similar patients who were treated with a placebo. The drug was effective in patients with all forms of heart failure, including those whose heart muscle is abnormally stiff (preserved ejection fraction) and for whom there is currently no effective treatment, according to research presented at the American College of Cardiology s 70th Annual Scientific Session.

Deepakl bhattEmily hendersonAmerican college of cardiologyHarvard medical schoolWomen hospital heart vascular centerAmerican collegeAnnual scientificHospital heartVascular centerNew england journalHeart failureBlood sugarMedical schoolஎமிலி ஹென்டர்சன்அமெரிக்கன் கல்லூரி ஆஃப் இருதயவியல்ஹார்வர்ட் மருத்துவ பள்ளி